Advertisement
Screener

Scilex Holding Company (SCLX) Foreign Currency Transaction Gain (Loss), before Tax

2.7 / 5 stars · 25/47 Roast Me

Scilex Holding Company Foreign Currency Transaction Gain (Loss), before Tax

Scilex Holding Company (SCLX) reported Foreign Currency Transaction Gain (Loss), before Tax of -$150.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Income Statement › Other Income

us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2026-08-14

  • Scilex Holding Company foreign currency transaction gain (loss), before tax for the quarter ending 2026-06-30 was -$150.00K.
  • Scilex Holding Company foreign currency transaction gain (loss), before tax for the quarter ending 2026-03-31 was -$279.00K, a 7075.00% decline year-over-year.
  • Scilex Holding Company foreign currency transaction gain (loss), before tax for the quarter ending 2025-12-31 was $183.00K, a 1425.00% increase year-over-year.
  • Scilex Holding Company foreign currency transaction gain (loss), before tax for the quarter ending 2025-09-30 was -$2.00K.
  • Scilex Holding Company foreign currency transaction gain (loss), before tax for fiscal 2025 was $86.00K.
  • Scilex Holding Company foreign currency transaction gain (loss), before tax for fiscal 2024 was -$45.00K.
  • Scilex Holding Company foreign currency transaction gain (loss), before tax for fiscal 2023 was -$118.00K.
  • Scilex Holding Company foreign currency transaction gain (loss), before tax for fiscal 2022 was -$66.00K.
Period endForeign Currency Transaction Gain (Loss), before Tax 3 monthForeign Currency Transaction Gain (Loss), before Tax 6 monthForeign Currency Transaction Gain (Loss), before Tax 9 monthForeign Currency Transaction Gain (Loss), before Tax 12 month
2026-06-30-$150.00K
10-Q · filed 2026-08-14
-$429.00K
10-Q · filed 2026-08-14
-$246.00K
derived: sum of 3 quarters · filed 2026-08-14
-$248.00K
derived: sum of 4 quarters · filed 2026-08-14
2026-03-31-$279.00K
10-Q · filed 2026-05-20
-$96.00K
derived: sum of 2 quarters · filed 2026-05-20
-$98.00K
derived: sum of 3 quarters · filed 2026-05-20
-$197.00K
derived: sum of 4 quarters · filed 2026-08-14
2025-12-31$183.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10
$181.00K
derived: sum of 2 quarters · filed 2026-04-10
$82.00K
derived: sum of 3 quarters · filed 2026-08-14
$86.00K
10-K · filed 2026-04-10
2025-09-30-$2.00K
10-Q · filed 2025-11-14
-$101.00K
derived: sum of 2 quarters · filed 2026-08-14
-$97.00K
10-Q · filed 2025-11-14
-$85.00K
derived: sum of 4 quarters · filed 2026-08-14
2025-06-30-$99.00K
10-Q · filed 2026-08-14
-$95.00K
10-Q · filed 2026-08-14
-$83.00K
derived: sum of 3 quarters · filed 2026-08-14
-$129.00K
derived: sum of 4 quarters · filed 2026-08-14
2025-03-31$4.00K
10-Q · filed 2026-05-20
$16.00K
derived: sum of 2 quarters · filed 2026-05-20
-$30.00K
derived: sum of 3 quarters · filed 2026-05-20
-$35.00K
derived: sum of 4 quarters · filed 2026-05-20
2024-12-31$12.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10
-$34.00K
derived: sum of 2 quarters · filed 2026-04-10
-$39.00K
derived: sum of 3 quarters · filed 2026-04-10
-$45.00K
10-K · filed 2026-04-10
2024-09-30-$46.00K
10-Q · filed 2025-11-14
-$51.00K
derived: sum of 2 quarters · filed 2025-11-14
-$57.00K
10-Q · filed 2025-11-14
-$145.00K
derived: sum of 4 quarters · filed 2025-11-14
2024-06-30-$5.00K
10-Q · filed 2025-08-13
-$11.00K
10-Q · filed 2025-08-13
-$99.00K
derived: sum of 3 quarters · filed 2025-08-13
-$106.00K
derived: sum of 4 quarters · filed 2025-08-13
2024-03-31-$6.00K
10-Q · filed 2025-05-14
-$94.00K
derived: sum of 2 quarters · filed 2025-05-14
-$101.00K
derived: sum of 3 quarters · filed 2025-05-14
-$104.00K
derived: sum of 4 quarters · filed 2025-05-14
2023-12-31-$88.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31
-$95.00K
derived: sum of 2 quarters · filed 2025-03-31
-$98.00K
derived: sum of 3 quarters · filed 2025-03-31
-$118.00K
10-K · filed 2025-03-31
2023-09-30-$7.00K
10-Q · filed 2025-01-17
-$10.00K
derived: sum of 2 quarters · filed 2025-01-17
-$30.00K
10-Q · filed 2025-01-17
-$135.00K
derived: sum of 4 quarters · filed 2025-01-17
2023-06-30-$3.00K
10-Q · filed 2024-08-13
-$23.00K
10-Q · filed 2024-08-13
-$128.00K
derived: sum of 3 quarters · filed 2024-08-13
-$97.00K
derived: sum of 4 quarters · filed 2024-08-13
2023-03-31-$20.00K
10-Q · filed 2024-05-13
-$125.00K
derived: sum of 2 quarters · filed 2024-05-13
-$94.00K
derived: sum of 3 quarters · filed 2024-05-13
-$82.00K
derived: sum of 4 quarters · filed 2024-05-13
2022-12-31-$105.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12
-$74.00K
derived: sum of 2 quarters · filed 2024-03-12
-$62.00K
derived: sum of 3 quarters · filed 2024-03-12
-$66.00K
10-K · filed 2024-03-12
2022-09-30$31.00K
10-Q · filed 2023-11-14
$43.00K
derived: sum of 2 quarters · filed 2023-11-14
$39.00K
10-Q · filed 2023-11-14
2022-06-30$12.00K
10-Q · filed 2023-08-11
$8.00K
10-Q · filed 2023-08-11
2022-03-31-$4.00K
10-Q · filed 2023-05-12
2021-12-31-$54.00K
10-K · filed 2024-03-12
2020-12-31$2.00K
10-K · filed 2023-03-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
Metagenomi Therapeutics, Inc. (MGX)United States$0.044B-0.48
LeonaBio, Inc. (LONA)United States$0.047B-0.61
Instil Bio, Inc. (TIL)United States$0.048B-1.73
Tevogen Inc. (TVGN)United States$0.049B
aTYR PHARMA INC (ATYR)United States$0.033B-0.98
Quince Therapeutics, Inc. (QNCX)United States$0.031B
CEL SCI CORP (CVM)United States$0.030B-0.81
Inmune Bio, Inc. (INMB)United States$0.056B-2.48
ImageneBio, Inc. (IMA)United States$0.056B-1.31
BioAtla, Inc. (BCAB)United States$0.058B-0.21